# Tiffany Inglis

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/tiffany-inglis
Canonical HTML page: https://getyourbrief.com/entity/tiffany-inglis

## Timeline

- **2028-01-01**: Runway Horizon — Current capital projected to fund operations through significant commercial milestones.
- **2028-01-01**: Cash Runway Limit — Current capital projected to fund operations through this period across commercial milestones.
- **2026-12-31**: 2026 Target — Goal to reach 15-17 states and operate 5-7 live partner programs.
- **2026-12-31**: Commercial Target — Goal to reach 15-17 states and 5-7 live partner programs.
- **2026-03-18**: Q4 Earnings Call — Management outlines pivot from R&D to commercial scaling and state-level engagement.
- **2026-03-18**: Q4 Earnings Call — Management confirms runway through 2028 and details PRIME study impact.
- **2025-12-31**: Fiscal Year End — Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
- **2025-12-31**: Fiscal Year End — Sera concludes 2025 with $95.8M in cash and a narrowed net loss.

## Recent coverage (2 stories, network-wide)

### Sera Prognostics Leverages PRIME Study Success for 2028 Commercial Runway
2026-03-19 00:17:38 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 6

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
Full story: https://getbiobrief.com/story/sera-prognostics-q4-2025-earnings-prime-study-commercialization

### Sera Prognostics Targets 2028 Runway as PRIME Study Bolsters Commercial Pivot
2026-03-19 00:16:48 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 6

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.
Full story: https://gethealthbrief.com/story/sera-prognostics-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.